<DOC>
	<DOCNO>NCT00936897</DOCNO>
	<brief_summary>This multi-center , randomize , open-label , parallel group , study conduct United States Europe postmenopausal woman . Approximately 800 subject randomize across 65 site 1:1 ratio either denosumab 60mg SC Q6M , ibandronate 150mg PO QM .</brief_summary>
	<brief_title>A Study Evaluate Safety Efficacy Denosumab Ibandronate Postmenopausal Women Sub-Optimally Treated With Daily Weekly Bisphosphonates</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Osteoporosis , Postmenopausal</mesh_term>
	<mesh_term>Ibandronic acid</mesh_term>
	<mesh_term>Denosumab</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>Ambulatory , postmenopausal woman ( base medical history ) 55 year old screening Postmenopause define vaginal bleeding spot least 12 month If subject 55 59 year old uncertainty regard menopausal status , confirmation serum FSH ( &gt; = 50 mIU/mL ) serum estradiol ( &lt; = 20 pg/mL ) must obtain If subject 60 year old , evaluation FSH estradiol level need confirm menopausal status Have receive first prescription daily weekly bisphosphonate therapy least 1 month prior screening May receive raloxifene , calcitonin , prior initiation daily orweekly bisphosphonate therapy . 3 dos monthly bisphosphonate prior initiation daily weekly bisphosphonate therapy calcium , vitamin D Hormone replacement therapy ( e.g . estrogen use mitigation menopausal symptom ) Subject : Stopped daily weekly bisphosphonate therapy ( denoted nonpersistent ) least one month screen visit , Demonstrated low adherence therapy assess score less 6 OSMMAS Screening BMD ( g/cm2 ) value , lumbar spine OR total hip , occur within follow range , base particular scanner use : GE Lunar Lumbar spine 0.700 &lt; = BMD &lt; = 0.940 Total hip 0.504 &lt; = BMD &lt; = 0.756 Hologic Lumbar spine 0.607 &lt; = BMD &lt; = 0.827 Total hip 0.454 &lt; = BMD &lt; = 0.698 Both initial repeat DXA scan lumbar spine OR total hip must meet eligibility criterion . At least 2 lumbar vertebra must evaluable DXA . At least one hip must evaluable DXA ( eg , history either bilateral hip replacement pin hip ) Provide sign informed consent studyspecific procedure conduct Any disorder compromise ability subject give write informed consent and/or comply study procedure Current prior use medication prescribe osteoporosis treatment oral daily weekly bisphosphonate Contraindicated receive oral ibandronate 150mg PO QM , include Hypersensitivity ibandronate 150mg PO QM constituent ibandronate 150mg PO QM tablets Abnormalities esophagus , delay esophageal empty stricture achalasia Inability stand sit upright least 60 minute Administration follow treatment within 3 month screen Tibolone Anabolic steroids testosterone Glucocorticosteroids ( &gt; = 5 mg prednisone equivalent per day 10 day total cumulative dose &gt; = 50 mg ) Vitamin D deficiency [ 25 ( OH ) vitamin D level &lt; 20 ng/mL ( &lt; 49.9 nmol/L ) ] Repletion allow subject may rescreened Evidence follow per subject report , chart review central laboratory result : Significantly impair renal function determine estimate Glomerular Filtration Rate le 30mL/min/1.73 m2 determine central laboratory Current hypo hypercalcemia base central laboratory reference range Active gastric duodenal ulcer ; history significant gastrointestinal bleed require hospitalization transfusion Known test positive human immunodeficiency virus , hepatitis C virus , hepatitis B surface antigen Malignancy ( except fully resect cutaneous basal cell squamous cell carcinoma , cervical breast ductal carcinoma situ ) within last 5 year Any metabolic bone disease secondary cause bone loss control may interfere interpretation finding Previous participation clinical trial denosumab 60mg SC Q6M ( regardless treatment ) Received solid organ bone marrow transplant Any laboratory abnormality , opinion investigator , prevent subject complete study interfere interpretation study result Known sensitivity mammalian cell derive drug product Known intolerance calcium supplement Currently enrol yet complete least 1 month since end investigational device drug trial ( ) Any physical psychiatric disorder , opinion investigator , prevent subject complete study interfere interpretation study result Evidence alcohol substanceabuse within last 12 month investigator believe would interfere understand complete study</criteria>
	<gender>Female</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
</DOC>